kx2-391 Report issue

Small molecule Experimental First in Class
AACT ChEMBL MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: O=C(Cc1ccc(-c2ccc(OCCN3CCOCC3)cc2)cn1)NCc1ccccc1
  • InChIKey: HUNGUWOZPQBXGX-UHFFFAOYSA-N
  • Mol. Mass: 431.54
  • ALogP: 3.32
  • ChEMBL Molecule:
    kx2-391  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: No

Alternative names

kx-01 | kx2-391 | n-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)acetamide

Organizations (8)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Keratosis, Actinic

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Breast Neoplasms (Phase 1/Phase 2)

Intestinal Neoplasms (Phase 1)

Keratosis, Actinic (Phase 3)

Leukemia, Myeloid, Acute (Phase 1)

Lymphoma (Phase 1)

Lymphoproliferative Disorders (Phase 1)

Neoplasms (Phase 1/Phase 2)

Prostatic Neoplasms, Castration-Resistant (Phase 2)

Stomach Neoplasms (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue